Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners
- PMID: 9451711
- DOI: 10.1007/BF01285547
Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners
Abstract
The massive and prolonged stimulation of serotonin (5-HT)-release and the increased dopaminergic activity are responsible for the acute psychomimetic and psychostimulatory effects of 3,4-methylenedioxy-methamphetamine (MDMA, "ecstasy") and its congeners. In vulnerable subjects, at high doses or repeated use, and under certain unfavorable conditions (crowding, high ambient temperature), severe, in some cases fatal, averse systemic reactions (hyperthermia, serotonin-syndrome) may occur during the first few hours. Animal experiments revealed the existence of similar differences in vulnerability and similar dose- and context-related influences on a similar sequence of acute responses. The severity of these acute systemic responses is closely related to the severity of the long-term damage to 5-HT axon terminals caused by the administration of substituted amphetamines. Attempts to identify the mechanisms involved in this selective degeneration of 5-HT presynapses brought to light a multitude of different factors and conditions which either attenuate or potentiate the loss of 5-HT terminals caused by MDMA and related amphetamine derivatives. These puzzling observations suggest that the degeneration of 5-HT presynapses represents only the final step in a sequence of events which compromise the ability of 5-HT terminals to maintain their functional and structural integrity. Substituted amphetamines selectively tax energy metabolism in 5-HT presynapses through their ability to exchange with 5-HT and to dissipate transmembrane ion gradients. The active carrier systems in the vesicular and presynaptic membrane operate at a permanently activated state. The resulting energy deficit can no longer adequately restored by the 5-HT presynapses when their availability of substrates for ATP production is additionally reduced by the hyperthermic and other energy consuming reactions which are elicited by the systemic administration of substituted amphetamines. The exhaustion of energy in 5-HT nerve terminals compromised all energy-requiring endogenous mechanisms involved in the regulation of transmembrane-ion exchange, internal Ca(++)-homeostasis, prevention of oxidative stress, detoxification, and repair. Above a critical threshold the failure of these self-protective mechanisms will lead to the degeneration of the 5-HT axon terminals. Based on the role of 5-HT as a global modulatory transmitter-system involved in the stabilization and integration of impulse flow between distributed multifocal neuronal networks, the partial loss of 5-HT presynapses must be expected to impair the ability of these networks to maintain the integrity of signal flow pattern, and increase the likelihood of switching to unstable information processing. Behavioral responding may therefore become more dominated by activities generated in individual networks, and hitherto "buffered" personality traits and predisposition may become manifested as defined psychiatric syndromes in certain predisposed subjects.
Similar articles
-
Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love").Neuropharmacology. 2006 Jan;50(1):69-80. doi: 10.1016/j.neuropharm.2005.08.006. Epub 2005 Sep 26. Neuropharmacology. 2006. PMID: 16188283
-
Altered forebrain neurotransmitter responses to immobilization stress following 3,4-methylenedioxymethamphetamine.Neuroscience. 2002;110(1):41-8. doi: 10.1016/s0306-4522(01)00539-5. Neuroscience. 2002. PMID: 11882371
-
Studies on the mechanisms underlying amiloride enhancement of 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats.Eur J Pharmacol. 2007 May 21;562(3):198-207. doi: 10.1016/j.ejphar.2007.01.049. Epub 2007 Feb 1. Eur J Pharmacol. 2007. PMID: 17320075
-
3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions.J Pharmacol Exp Ther. 2001 Jun;297(3):846-52. J Pharmacol Exp Ther. 2001. PMID: 11356903 Review.
-
MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.J Psychopharmacol. 2006 Mar;20(2):147-63. doi: 10.1177/0269881106063268. J Psychopharmacol. 2006. PMID: 16510474 Review.
Cited by
-
A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain.Br J Pharmacol. 2001 Dec;134(8):1711-23. doi: 10.1038/sj.bjp.0704435. Br J Pharmacol. 2001. PMID: 11739248 Free PMC article.
-
First Death Involving 4-Fluoroethylphenidate (4F-EPH): Case Report, User Experiences, and Review of the Related Literature.Acad Forensic Pathol. 2022 Dec;12(4):149-166. doi: 10.1177/19253621221142480. Epub 2022 Dec 1. Acad Forensic Pathol. 2022. PMID: 36545302 Free PMC article.
-
The Netherlands XTC Toxicity (NeXT) study: objectives and methods of a study investigating causality, course, and clinical relevance.Int J Methods Psychiatr Res. 2005;14(4):167-85. doi: 10.1002/mpr.6. Int J Methods Psychiatr Res. 2005. PMID: 16395871 Free PMC article.
-
Serotonergic dysfunction: brain imaging and behavioral correlates.Cogn Affect Behav Neurosci. 2006 Mar;6(1):53-61. doi: 10.3758/cabn.6.1.53. Cogn Affect Behav Neurosci. 2006. PMID: 16869229 Review.
-
White-matter abnormalities in brain during early abstinence from methamphetamine abuse.Psychopharmacology (Berl). 2010 Mar;209(1):13-24. doi: 10.1007/s00213-009-1761-7. Epub 2010 Jan 27. Psychopharmacology (Berl). 2010. PMID: 20101394 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical